Centessa Pharmaceuticals (NASDAQ:CNTA) Releases Earnings Results

Centessa Pharmaceuticals (NASDAQ:CNTA) issued its earnings results on Tuesday. The company reported ($0.52) earnings per share (EPS) for the quarter, FiscalAI reports.

Centessa Pharmaceuticals Price Performance

CNTA stock traded up $0.06 during midday trading on Thursday, reaching $39.66. 765,965 shares of the company’s stock traded hands, compared to its average volume of 2,321,156. The company has a 50-day simple moving average of $33.45 and a two-hundred day simple moving average of $28.06. Centessa Pharmaceuticals has a 1-year low of $10.95 and a 1-year high of $40.26. The company has a market cap of $5.92 billion, a price-to-earnings ratio of -26.98 and a beta of 1.13. The company has a quick ratio of 8.57, a current ratio of 8.57 and a debt-to-equity ratio of 0.21.

Insiders Place Their Bets

In related news, insider Karen M. Anderson sold 41,076 shares of the firm’s stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the completion of the sale, the insider directly owned 62,085 shares of the company’s stock, valued at $1,870,000.20. This trade represents a 39.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Gregory M. Weinhoff sold 73,196 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.33, for a total value of $1,927,250.68. Following the sale, the insider directly owned 65,925 shares of the company’s stock, valued at $1,735,805.25. This represents a 52.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 309,112 shares of company stock valued at $8,424,535 over the last ninety days. Insiders own 7.09% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Private Advisor Group LLC bought a new position in Centessa Pharmaceuticals in the 1st quarter valued at $238,000. Y Intercept Hong Kong Ltd boosted its position in Centessa Pharmaceuticals by 742.3% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 96,367 shares of the company’s stock valued at $3,828,000 after buying an additional 84,926 shares during the last quarter. Pictet Asset Management Holding SA bought a new position in Centessa Pharmaceuticals in the 1st quarter valued at $3,849,000. Caitong International Asset Management Co. Ltd bought a new position in Centessa Pharmaceuticals in the 4th quarter valued at $80,000. Finally, T. Rowe Price Investment Management Inc. boosted its position in Centessa Pharmaceuticals by 7,580.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after buying an additional 1,516 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

CNTA has been the subject of a number of recent research reports. B. Riley Financial cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Leerink Partners cut Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and increased their target price for the stock from $36.00 to $40.00 in a report on Wednesday, April 1st. Lifesci Capital cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 1st. Truist Financial cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target for the company. in a report on Monday, April 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Monday, April 20th. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $40.70.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.